ALTEOGEN company profile
Company profile
ALTEOGEN has 181 employees and is headquartered in Daejeon, South Korea.
ALT-P1, a long-acting human growth hormone in a Phase IIa trial, and ALT-Q2, a coagulation factor VII product for hemophilia, anchor the development pipeline of ALTEOGEN Inc. Its oncology candidates include ALT-P7, a targeted drug for breast and gastric cancer in Phase I, and ALT-Q5, an antibody-drug conjugate for ovarian cancer built on its NexMab ADC technology. The company also develops ALT-LS2, a subcutaneous form of trastuzumab for breast and gastric cancer, and works with Kissei Pharmaceutical on ALT-L9, a biosimilar of Eylea, with Cristalia on ALT-L2, a biosimilar of Herceptin, and with Biogen Inc. on subcutaneous formulations of biologics using ALT-B4.
In the fiscal year ended December 2025, revenue reached 215.9 billion won and net income 141.7 billion won. The company, founded in 2008, employs 181 people and is headquartered in Daejeon, South Korea.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- South Korea
- Headquarters
- 62, Yuseong-daero, 34054, Daejeon
- Employees
- 181
- Chief executive
- Soon-Jae Park
- Founded
- 2008
- Fiscal year
- January - December
- Listing
- 196170 · KRX
- Currency
- KRW
- ISIN
- KR7196170005
- Website
- alteogen.com
ALTEOGEN and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ALTEOGEN196170 | South Korea | $9.17B | 181 | 47.2% | 97.1 |
| Genscript Biotech1548 | Hong Kong SAR China | $8.83B | 6,135 | 14.9% | — |
| Haisco Pharmaceutical Group002653 | China | $9.79B | 5,597 | 21.1% | 50.6 |
| Akeso9926 | Hong Kong SAR China | $7.6B | 4,082 | -30.7% | — |
| Pharmaron Beijing300759 | China | $11.45B | 25,088 | 14.0% | 42.4 |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $12.49B | 22,838 | 28.2% | 36.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
